Providing insurance coverage for multicancer early detection (MCED) tests is vital to reduce disparities in access, said Patricia Deverka, MD, MS, senior researcher, deputy director at the Center for Translational and Policy Research and Precision Medicine, University of California San Francisco.
Patricia Deverka, MD, MS, senior researcher, deputy director at the Center for Translational and Policy Research and Precision Medicine, University of California San Francisco, talks about the ways multicancer early detection (MCED) tests can reduce disparities.
Transcript
How can MCED tests both reduce or widen disparities in cancer screening, and what are some possible solutions?
I think there are some theoretical ways that these tests could reduce disparities. I say that because, currently, we don't have clear evidence that these tests have net benefits; we haven't demonstrated clinical utility yet. With that sort of caveat, I do think that, potentially, the ease of use of a single blood draw could potentially reduce disparities if there were barriers to access to screening tests for certain disadvantaged populations, whether that be geography or socioeconomic status or cultural beliefs, so that may help to reduce disparities.
I also think if they can detect more aggressive cancers, we know that those disproportionately affect minority patients, so that could potentially be a way to reduce disparities. Frankly, most people can't pay $1000 out-of-pocket for 1 of these tests. The biggest way to reduce disparities, again assuming that these tests have clinical utility, is to provide insurance coverage. Many screening tests, for example those with the USPSTF rating of A or B, have first dollar coverage, meaning there's no out-of-pocket expense for access to the screening test. I think all of those would be important because, currently, the only people right now that have access to the test are people that can pay out-of-pocket. It may also be that some physicians that treat the majority of their patient population are disadvantaged patients. They may need additional educational support to make sure that there's appropriate use of these tests.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More